TED
10.14.20
Tepezza Data From Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)Source: Horizon Therapeutics
07.31.20
New Topline Tepezza Data Underscore its Efficacy in Potential for Retreatment in People Living with Thyroid Eye Disease (TED)Source: Horizon Therapeutics
07.01.20
New Initiative Encourages the Graves’ Disease Community to FOCUS on Eye HealthSource: Horizon Therapeutics
05.14.20
New Data on the Pharmacokinetic Profile of Tepezza Reinforce the Labeled Dosing RegimenSource: Horizon Therapeutics
05.11.20
US Physician Survey Illustrates the Impact of Thyroid Eye Disease on Patient Quality of LifeSource: Horizon Therapeutics
01.23.20
The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial of Tepezza for Thyroid Eye DiseaseSource: Horizon Therapeutics
12.16.19
FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)Source: Horizon Therapeutics
12.13.19
Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye DiseaseSource: Horizon Therapeutics
11.22.19
Horizon Therapeutics Launches New Online Community Connecting People Living With Thyroid Eye DiseaseSource: Horizon Therapeutics